Inside Selling: Ernest Mario Unloaded 13,370 Shares of Celgene (CELG); Shorts at LIG ASSETS (LIGA) Lowered By 75.22%

LIG ASSETS INC (OTCMKTS:LIGA) had a decrease of 75.22% in short interest. LIGA’s SI was 16,700 shares in February as released by FINRA. Its down 75.22% from 67,400 shares previously. The stock increased 5.97% or $0.0004 during the last trading session, reaching $0.0071. About shares traded. LIG Assets, Inc. (OTCMKTS:LIGA) has 0.00% since February 27, 2017 and is . It has underperformed by 16.70% the S&P500.

A few days ago, the director of Celgene Corp, Mr. Ernest Mario, sold amount of shares – 13,370, totalling $1,263,298 USD, based on $94.5 per share. More information about the deal dated 26-02-2018, could be found ready for use online in a public form on the SEC website here. Ernest Mario today holds 55,728 shares which make up exactly 0.01% of the New Jersey-Company’s total market cap (Market Capitalization is a measurement of business value based on share price and number of shares outstanding).

LIG Assets, Inc. focuses on residential and commercial real estate business in the state of Texas. The company has market cap of $16.06 million. The firm purchases commercial and residential real estate properties for resale and rental. It has a 0.79 P/E ratio. It also invests, acquires, finances, and manages commercial properties, such as hotels, apartments, condos, retail, and office buildings; and offers loans for single family homes.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.17, from 1.34 in 2017Q2. It worsened, as 44 investors sold Celgene Corporation shares while 457 reduced holdings. 133 funds opened positions while 451 raised stakes. 603.99 million shares or 0.25% more from 602.51 million shares in 2017Q2 were reported. Gagnon Secs Ltd Liability Com stated it has 0.1% of its portfolio in Celgene Corporation (NASDAQ:CELG). Sterling Mgmt Ltd Liability owns 30,800 shares. Seatown Holding Pte Limited owns 39,995 shares. Atlantic Group Limited reported 900,053 shares or 0.59% of all its holdings. Blair William And Company Il holds 0.79% or 718,443 shares. Tokio Marine Asset Ltd reported 94,855 shares. Bb Biotech Ag holds 12.85% or 3.18 million shares in its portfolio. Schmidt P J Inv Mgmt owns 0.07% invested in Celgene Corporation (NASDAQ:CELG) for 1,515 shares. Tompkins Financial Corporation reported 17,437 shares stake. Btim reported 6,890 shares or 0.02% of all its holdings. Numeric Ltd Llc accumulated 0.08% or 67,100 shares. Brinker Incorporated holds 43,623 shares or 0.26% of its portfolio. Sandy Spring Financial Bank holds 41,303 shares or 0.58% of its portfolio. Mathes Inc invested in 0.14% or 2,040 shares. Old Mutual Customised Solutions (Proprietary) Limited holds 0.51% or 25,949 shares in its portfolio.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on April, 26. They expect $1.78 earnings per share, up 16.34% or $0.25 from last year’s $1.53 per share. CELG’s profit will be $1.34B for 13.55 P/E if the $1.78 EPS becomes a reality. After $1.87 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts -4.81% negative EPS growth.

Since September 5, 2017, it had 1 buy, and 4 insider sales for $4.31 million activity. CASEY MICHAEL D also sold $1.29 million worth of Celgene Corporation (NASDAQ:CELG) on Tuesday, September 5. KAPLAN GILLA had sold 18,500 shares worth $1.77 million. 1,727 shares were sold by Curran Terrie, worth $248,498 on Monday, September 25. Alles Mark J also bought $299,594 worth of Celgene Corporation (NASDAQ:CELG) shares.

Among 33 analysts covering Celgene Corporation (NASDAQ:CELG), 19 have Buy rating, 2 Sell and 12 Hold. Therefore 58% are positive. Celgene Corporation has $190 highest and $83 lowest target. $133.21’s average target is 38.06% above currents $96.49 stock price. Celgene Corporation had 132 analyst reports since July 21, 2015 according to SRatingsIntel. On Friday, October 20 the stock rating was maintained by SunTrust with “Buy”. The stock of Celgene Corporation (NASDAQ:CELG) earned “Outperform” rating by BMO Capital Markets on Friday, October 27. The stock of Celgene Corporation (NASDAQ:CELG) has “Outperform” rating given on Friday, December 4 by Wells Fargo. The firm has “Buy” rating given on Thursday, October 26 by Cowen & Co. The company was maintained on Thursday, October 26 by Robert W. Baird. As per Friday, July 28, the company rating was maintained by Stifel Nicolaus. The rating was maintained by Cowen & Co on Friday, August 4 with “Buy”. As per Tuesday, November 8, the company rating was initiated by Mizuho. On Tuesday, April 19 the stock rating was maintained by Credit Suisse with “Outperform”. The stock of Celgene Corporation (NASDAQ:CELG) has “Underweight” rating given on Thursday, October 5 by Morgan Stanley.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $72.58 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 26.51 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.